Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Herbert Irving Comprehensive Cancer Center Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

NCT03304080
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases
Interventions
Anastrozole, Palbociclib, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

NCT00017446
View directory record Official record
Conditions
Sarcoma
Interventions
CP4071
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

NCT00003718
View directory record Official record
Conditions
Endometrial Cancer, Ovarian Cancer, Sarcoma
Interventions
temozolomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer

NCT00027833
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ALVAC-CEA-B7.1 vaccine, tetanus toxoid, FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Biological · Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Completed Phase 3 Interventional

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

NCT00049452
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Stamford, Connecticut • Paramus, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

NCT00012311
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 59 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Active, not recruiting Not applicable Interventional

Testing Gene PilotLX With Latinx Cancer Patients

NCT06476938
View directory record Official record
Conditions
Cancer
Interventions
Gene PilotLX
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Camden, New Jersey • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 16, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00004204
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
10
States / cities
Stanford, California • Miami Beach, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

NCT00017680
View directory record Official record
Conditions
Amyloidosis
Interventions
Melphalan, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2008 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

NCT00008307
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma

NCT00026416
View directory record Official record
Conditions
Sarcoma
Interventions
recombinant interferon alfa, thalidomide, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

NCT00008190
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 16, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00003124
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Completed Phase 3 Interventional

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

NCT00008203
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, recombinant interferon gamma, carboplatin, cyclophosphamide, cyclosporine, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 16, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix

NCT00003065
View directory record Official record
Conditions
Cervical Cancer
Interventions
filgrastim, paclitaxel, topotecan hydrochloride
Biological · Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer

NCT00007982
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Head and Neck Cancer, Lymphoma
Interventions
filgrastim, carmustine, cisplatin, cyclophosphamide, etoposide, thiotepa, adjuvant therapy, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma

NCT00033709
View directory record Official record
Conditions
Sarcoma
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 1Phase 2 Interventional

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00002775
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed No phase listed Observational

Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

NCT00899119
View directory record Official record
Conditions
Lymphoma
Interventions
leukapheresis
Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

NCT00003284
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

NCT00003066
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003560
View directory record Official record
Conditions
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 4:41 PM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

NCT00003633
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 16, 2026, 4:41 PM EDT